For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 63,104 | |||
| General and administrative | 20,779 | |||
| Total operating expenses | 83,883 | |||
| Loss from operations | -83,883 | |||
| Interest income | 1,741 | |||
| Change in fair value of warrant liability | -8,528 | |||
| Other expense, net | -2,187 | |||
| Total other income, net | 8,082 | |||
| Net loss and comprehensive loss | -75,801 | |||
| Basic EPS | -3.95 | |||
| Diluted EPS | -3.95 | |||
| Basic Average Shares | 19,168,110 | |||
| Diluted Average Shares | 19,168,110 | |||
Jasper Therapeutics, Inc. (JSPRW)
Jasper Therapeutics, Inc. (JSPRW)